Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292104 | 0.87 | CYP1A2 (0.35) | CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL11106621 | 0.75 | — | — | |
| SCHEMBL8960374 | 0.74 | TSHR (0.35) | — | |
| SCHEMBL142354 | 0.71 | — | — | |
| SCHEMBL10624575 | 0.68 | — | — | |
| SCHEMBL2860348 | 0.67 | ALDH1A1 (0.36) | CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL8556309 | 0.66 | CRHR1 (0.38) | — | |
| SCHEMBL9790451 | 0.66 | LTA4H (0.41) | ALDH1A1 | |
| SCHEMBL7680807 | 0.65 | — | — | |
| SCHEMBL11017179 | 0.65 | CYP1A2 (0.80) | CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227965-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | claimed |
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-14 | — | — | US | claimed |
| EP-2758386-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | claimed |
| WO-2013041655-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-03-28 | — | — | WO | claimed |
| EP-3420362-A1 | ANTIBODIES | The Binding Site Group Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017144903-A1 | ANTIBODIES | THE BINDING SITE GROUP LIMITED (GB) | 2017-08-31 | — | — | WO | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9227965-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-14 | — | — | US | disclosed |
| EP-2758386-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-0001451-B1 | WATER-SOLUBLE AZO-PHTHALOCYANINE FIBRE-REACTIVE DYESTUFFS, THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1981-09-23 | — | — | EP | disclosed |
| EP-0001629-B1 | WATER-SOLUBLE, FIBRE-REACTIVE, GREEN AZO-PHTHALOCYANINE DYESTUFFS, THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1981-08-12 | — | — | EP | disclosed |
| US-4270918-A | METALLIZED TRIAZINE-FUNCTIONAL MONOAZO DYE | CIBA-GEIGY CORPORATION (US) | 1981-06-02 | — | — | US | disclosed |
| US-4204056-A | Process and intermediates for preparing fiber-reactive phthalocyanine dyes | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-05-20 | — | — | US | disclosed |
| US-4191686-A | FROM SULFONYL HALIDE SUBSTITUTED PARENT BY AMIDATION WITH AROMATIC DIAMINE, DIAZOTIZING, COUPLING TO KETO SUCCINIC ESTER, CYCLIZING, COUPLING TO REACTIVE MOIETY | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| EP-0001614-A1 | Water-soluble, fibre-reactive, green azo-phthalocyanine dyestuffs, their preparation and their application, as well as the phthalocyanine pyrazolone intermediates and their preparation | CASSELLA Aktiengesellschaft (DE) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001629-A1 | Water-soluble, fibre-reactive, green azo-phthalocyanine dyestuffs, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001451-A1 | Water-soluble azo-phthalocyanine fibre-reactive dyestuffs, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1979-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CPN1, CMA1, CYP51A1 | CYP1A2 430/4885ALDH1A1 1161/4885CYP2C19 54/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | CYP1A2 477/4885ALDH1A1 1031/4885CYP2C19 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.